Yusuke Nakamura to Vaccines, Subunit
This is a "connection" page, showing publications Yusuke Nakamura has written about Vaccines, Subunit.
Connection Strength
1.349
-
Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer. Cancer Immunol Immunother. 2018 Sep; 67(9):1371-1380.
Score: 0.162
-
Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer. J Immunother. 2018 May; 41(4):201-207.
Score: 0.160
-
Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017 May; 50(5):1655-1662.
Score: 0.148
-
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. J Exp Clin Cancer Res. 2017 02 28; 36(1):36.
Score: 0.147
-
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016 05; 166-167:48-58.
Score: 0.138
-
Guidance for peptide vaccines for the treatment of cancer. Cancer Sci. 2014 Jul; 105(7):924-31.
Score: 0.122
-
A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med. 2014 Mar 10; 12:63.
Score: 0.120
-
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012 Oct; 41(4):1297-304.
Score: 0.107
-
Cancer vaccines. Clin Adv Hematol Oncol. 2011 Oct; 9(10):778-9.
Score: 0.101
-
miR-125b-1 and miR-378a are predictive biomarkers for the efficacy of vaccine treatment against colorectal cancer. Cancer Sci. 2017 Nov; 108(11):2229-2238.
Score: 0.038
-
Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Cancer Sci. 2017 Jul; 108(7):1452-1457.
Score: 0.038
-
Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2017 01; 66(1):17-24.
Score: 0.036
-
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 2015 Jan 15; 21(2):312-21.
Score: 0.031